Literature DB >> 8564955

Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.

F Eisinger1, D Stoppa-Lyonnet, M Longy, F Kerangueven, T Noguchi, C Bailly, A Vincent-Salomon, J Jacquemier, D Birnbaum, H Sobol.   

Abstract

Histoprognostic grade is a determinant parameter to select the initial therapeutic strategy in breast cancer. Our aim was to analyze the grade repartition in BRCA1-associated breast cancer (BC) and to explore the possible connections between grade and the BRCA1 gene function. We first compared 27 BRCA1-associated BCs from 14 families with 4,461 cases from an administrative district registry and 242 cases from a hospital-based registry, matching for grade and constitutive elements, and then considered their repartition in families. We observed a prevalence of grade 3 (P < 0.0001) in BRCA1-associated BC. This was attributed mainly to nuclear polymorphism (P < 0.0001), mitotic activity (P < 0.0001), and tubular differentiation (P = 0.0004), implying that BRCA1-associated BCs are highly proliferating tumors. Moreover, it is suggested that grade segregates as a genetic trait within families (P = 0.0015), and this was attributed to the mitotic index segregation only (P = 0.0005). Therefore grade, through its components, could be interpreted as the morphological translation of the BRCA1 germ line mutation. Thus, a genotype-phenotype correlation may exist between the type of mutation and the aggressiveness of the disease. These findings are bound to have an important impact in the care management of hereditary breast cancer at the individual and at the familial level and in the comprehensive approach of breast cancer development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8564955

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Functional domains of the BRCA1 and BRCA2 proteins.

Authors:  R Baer; W H Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-10       Impact factor: 2.673

Review 2.  BRCA1 and BRCA2 proteins: roles in health and disease.

Authors:  J A Duncan; J R Reeves; T G Cooke
Journal:  Mol Pathol       Date:  1998-10

Review 3.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

4.  Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.

Authors:  S A Vaziri; R R Tubbs; G Darlington; G Casey
Journal:  Mol Pathol       Date:  2001-08

Review 5.  Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.

Authors:  Kelly C Gast; Paul V Viscuse; Somaira Nowsheen; Tufia C Haddad; Robert W Mutter; Andrea E Wahner Hendrickson; Fergus J Couch; Kathryn J Ruddy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-01

6.  Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.

Authors:  Cameron M Scott; Ee Ming Wong; JiHoon Eric Joo; Pierre-Antoine Dugué; Chol-Hee Jung; Neil O'Callaghan; James Dowty; Graham G Giles; John L Hopper; Melissa C Southey
Journal:  Exp Mol Pathol       Date:  2018-11-10       Impact factor: 3.362

Review 7.  The pathology of familial breast cancer: Morphological aspects.

Authors:  S R Lakhani
Journal:  Breast Cancer Res       Date:  1999-10-27       Impact factor: 6.466

8.  Glut-1 Expression Correlates with Basal-like Breast Cancer.

Authors:  Yaser R Hussein; Sudeshna Bandyopadhyay; Assaad Semaan; Quratulain Ahmed; Bassam Albashiti; Tarek Jazaerly; Zeina Nahleh; Rouba Ali-Fehmi
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

9.  Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.

Authors:  Ava Kwong; L P Wong; H N Wong; F B F Law; E K O Ng; Y H Tang; W K Chan; D T K Suen; C Choi; L S Ho; K H Kwan; M Poon; T T Wong; K Chan; S W W Chan; M W L Ying; W C Chan; E S K Ma; J M Ford; D W West
Journal:  Hugo J       Date:  2010-04-10

10.  Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.

Authors:  Nadine Tung; Yihong Wang; Laura C Collins; Jennifer Kaplan; Hailun Li; Rebecca Gelman; Amy H Comander; Bridget Gallagher; Katharina Fetten; Karen Krag; Kathryn A Stoeckert; Robert D Legare; Dennis Sgroi; Paula D Ryan; Judy E Garber; Stuart J Schnitt
Journal:  Breast Cancer Res       Date:  2010-02-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.